We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00939354
First Posted: July 15, 2009
Last Update Posted: October 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Michele Columbo, M.D., Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
  Purpose
This study will investigate the importance of exhaled nitric oxide measurements in subjects with asthma age 65 and older. This group of patients has been ignored in most previous asthma studies.

Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements

Resource links provided by NLM:


Further study details as provided by Michele Columbo, M.D., Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.:

Primary Outcome Measures:
  • Exhaled Nitric Oxide (FENO) levels and their changes with time [ Time Frame: One year ]

Secondary Outcome Measures:
  • Correlations of FENO with subjects' demographics, comorbidities, treatment, symptoms, or spiromentric values [ Time Frame: One year ]

Enrollment: 30
Study Start Date: July 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with asthma over the age of 65 who are currently followed in our practice
Criteria

Inclusion Criteria:

  • Subjects with asthma over the age of 65 followed in our practice, non-smokers and able to give informed consent to participate in the study

Exclusion Criteria:

  • Smokers, subjects of diminished mental capacity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00939354


Sponsors and Collaborators
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Investigators
Principal Investigator: Albert S Rohr, M.D. Rohr and Columbo Associates
  More Information

Responsible Party: Michele Columbo, M.D., Co-Investigator, Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
ClinicalTrials.gov Identifier: NCT00939354     History of Changes
Other Study ID Numbers: F/N-R09-2839B
First Submitted: July 14, 2009
First Posted: July 15, 2009
Last Update Posted: October 29, 2015
Last Verified: October 2015

Keywords provided by Michele Columbo, M.D., Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.:
Asthma in subjects over the age of 65

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents